{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T10:49:27Z","timestamp":1791370167301,"version":"4.3.1"},"reference-count":106,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nephrol."],"abstract":"<jats:p>Epidemiological evidence demonstrates that atherosclerotic cardiovascular disease (ASCVD) is a major cause of death and disability in patients with chronic kidney disease (CKD). From the early stages of CKD, and in addition to specifically related conditions, the coexistence of traditional risk factors contributes to a process of accelerated atherosclerosis. In patients with CKD, increased cardiovascular risk persists even after correction of hypertension, dyslipidemia, and diabetes, indicating a residual risk likely related to additional subtle factors. Lipoprotein(a) [Lp(a)] is an LDL-like particle containing apoB100 covalently linked to apo(a) and is now recognized as a genetically determined risk factor for ASCVD. Following its initial description, Lp(a) aroused extraordinary interest, which then waned in the late-1990s due to the controversial results of some prospective studies and the lack of effective interventions to reduce its circulating levels. Over the past two decades, clinical studies have provided robust evidence supporting the causal and independent contribution of Lp(a) to ASCVD, also suggesting a significant contribution to residual cardiovascular risk. This contribution may be particularly significant in patients with CKD, who exhibit elevated Lp(a) levels from the earliest stages of disease. The recent development of potent Lp(a)-lowering drugs offers an exciting opportunity to effectively address residual risk in the general population and in patients with CKD. No data are yet available on their use in patients with CKD but pending future definition of their efficacy on cardiovascular outcomes, approval, dosing, and long-term safety, these drugs might possibly represent a useful tool for cardiovascular prevention in these patients.<\/jats:p>","DOI":"10.3389\/fneph.2026.1950030","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:50:16Z","timestamp":1791366616000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipoprotein(a): a potential target for the reduction of residual cardiovascular risk in patients with chronic kidney disease"],"prefix":"10.3389","volume":"6","author":[{"given":"Leonardo A.","family":"Sechi","sequence":"first","affiliation":[{"name":"Clinica Medica, Department of Medicine, University of Udine","place":["Udine, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bulfone","sequence":"additional","affiliation":[{"name":"Clinica Medica, Department of Medicine, University of Udine","place":["Udine, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vacca","sequence":"additional","affiliation":[{"name":"Clinica Medica, Department of Medicine, University of Udine","place":["Udine, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Comand","sequence":"additional","affiliation":[{"name":"Clinica Medica, Department of Medicine, University of Udine","place":["Udine, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Marcante","sequence":"additional","affiliation":[{"name":"Clinica Medica, Department of Medicine, University of Udine","place":["Udine, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Brosolo","sequence":"additional","affiliation":[{"name":"Clinica Medica, Department of Medicine, University of Udine","place":["Udine, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Pagano","sequence":"additional","affiliation":[{"name":"Clinica Medica, Department of Medicine, University of Udine","place":["Udine, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Catena","sequence":"additional","affiliation":[{"name":"Clinica Medica, Department of Medicine, University of Udine","place":["Udine, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1161\/01.ATV.8.4.398","article-title":"Lipoprotein Lp(a). A risk factor for myocardial infarction","volume":"8","author":"Hoefler","year":"1988","journal-title":"Arteriosclerosis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03510180065035","article-title":"A prospective study of lipoprotein(a) and the risk of myocardial infarction","volume":"270","author":"Ridker","year":"1993","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/ng.314","article-title":"Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease","volume":"41","author":"Tr\u00e9gou\u00ebt","year":"2009","journal-title":"Nat Genet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ije\/dyg070","article-title":"Mendelian randomization: can genetic epidemiology contribute to understanding environmental determinants of disease","volume":"32","author":"Davey Smith","year":"2003","journal-title":"Int J Epidemiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.102.10.1082","article-title":"Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies","volume":"102","author":"Danesh","year":"2000","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713363","article-title":"Lipoprotein(a): just an innocent bystander in arterial hypertension","volume":"24","author":"Brosolo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a)","volume":"64","author":"Willeit","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1001\/jama.1994.03510370051031","article-title":"Lipoprotein(a) levels and risk of coronary heart disease in men: the lipid research clinics coronary primary prevention trial","volume":"271","author":"Schaefer","year":"1994","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.5605","article-title":"Lipoprotein(a), C-reactive protein, and cardiovascular risk in primary and secondary prevention populations","volume":"9","author":"Small","year":"2024","journal-title":"JAMA Cardiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.5527\/wjn.v4.i3.374","article-title":"Early renal failure as a cardiovascular disease: focus on lipoprotein(a) and prothrombotic state","volume":"4","author":"Catena","year":"2015","journal-title":"World J Nephrol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.4.1226","article-title":"Abnormalities of glucose metabolism in patients with early renal failure","volume":"51","author":"Sechi","year":"2002","journal-title":"Diabetes"},{"key":"B15","article-title":"Increased fibrinogen levels and hemostatic abnormalities in patients with arteriolar nephrosclerosis: association with cardiovascular events","volume":"84","author":"Sechi","year":"2000","journal-title":"Thromb Haemost"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(00)00567-2","article-title":"Abnormalities of coagulation in hypertensive patients with reduced creatinine clearance","volume":"109","author":"Catena","year":"2000","journal-title":"Am J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-6-199809150-00006","article-title":"Increased serum lipoprotein(a) levels in patients with early renal failure","volume":"129","author":"Sechi","year":"1998","journal-title":"Ann Intern Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V351156","article-title":"Increased lipoprotein(a) in chronic renal failure","volume":"3","author":"Haffner","year":"1992","journal-title":"J Am Soc Nephrol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1172\/JCI116213","article-title":"Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a)","volume":"91","author":"Dieplinger","year":"1993","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.00621.x","article-title":"Lipoprotein(a) and apolipoprotein(a) isoforms and proteinuria in patients with moderate renal failure","volume":"56","author":"Sechi","year":"1999","journal-title":"Kidney Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540450045033","article-title":"Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension","volume":"277","author":"Sechi","year":"1997","journal-title":"JAMA"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/joim.20027","article-title":"Lipoprotein(a) concentrations and cardiovascular disease in patients with chronic kidney disease: results from the German Chronic Kidney Disease study","volume":"296","author":"Gruber","year":"2024","journal-title":"J Intern Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11883-025-01290-2","article-title":"Managing dyslipidemia in chronic kidney disease: implications for cardiovascular and renal risk","volume":"27","author":"Theofilis","year":"2025","journal-title":"Curr Atheroscler Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2275(20)37647-1","article-title":"Evidence that Lp[a] contains one molecule of apo[a] and one molecule of apoB: evaluation of amino acid analysis data","volume":"37","author":"Albers","year":"1996","journal-title":"J Lipid Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1093\/clinchem\/41.2.246","article-title":"Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a)","volume":"41","author":"Marcovina","year":"1995","journal-title":"Clin Chem"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.50.32403","article-title":"The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells","volume":"271","author":"Brunner","year":"1996","journal-title":"J Biol Chem"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/ng0495-424","article-title":"The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice","volume":"9","author":"Frazer","year":"1995","journal-title":"Nat Genet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.48.30387","article-title":"Characterization of multiple enhancer regions upstream of the apolipoprotein(a) gene","volume":"272","author":"Wade","year":"1997","journal-title":"J Biol Chem"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1042\/bj20030985","article-title":"A proximal tissue-specific module and a distal negative regulatory module control apolipoprotein(a) gene transcription","volume":"379","author":"Negi","year":"2004","journal-title":"Biochem J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.310700","article-title":"Novel lipoprotein(a) catabolism pathway via apolipoprotein(a) recycling: adding the plasminogen receptor PlgRKT to the list","volume":"120","author":"Yeang","year":"2017","journal-title":"Circ Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V111105","article-title":"Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure","volume":"11","author":"Kronenberg","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2022.04.008","article-title":"Lipoprotein(a) measurement issues: are we making a mountain out of a molehill","volume":"349","author":"Kronenberg","year":"2022","journal-title":"Atherosclerosis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(95)06070-t","article-title":"Whether, to what degree, and why lipoprotein(a) levels change over time","volume":"238","author":"Glueck","year":"1995","journal-title":"Clin Chim Acta"},{"key":"B35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","article-title":"Non-genetic influences on lipoprotein(a) concentrations","volume":"349","author":"Enkhmaa","year":"2022","journal-title":"Atherosclerosis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-026-01249-z","article-title":"Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies","volume":"23","author":"Galli","year":"2026","journal-title":"Nat Rev Cardiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/jhh.2009.34","article-title":"Residual cardiovascular risk in treated hypertension and hyperlipidaemia: the PRIME study","volume":"24","author":"Blacher","year":"2010","journal-title":"J Hum Hypertens"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002155","article-title":"Residual cardiovascular risk in individuals on blood pressure-lowering treatment","volume":"4","author":"Lieb","year":"2015","journal-title":"J Am Heart Ass"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200402000-00028","article-title":"Residual coronary risk in men aged 50-59 years treated for hypertension and hyperlipidaemia in the population: the PRIME study","volume":"22","author":"Blacher","year":"2004","journal-title":"J Hypertens"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.115.05961","article-title":"Genetic predisposition to higher blood pressure increases risk of incident hypertension and cardiovascular diseases in Chinese","volume":"66","author":"Lu","year":"2015","journal-title":"Hypertension"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2025.101280","article-title":"From LDL-C to lipoprotein(a)-those who fail to learn from history are doomed to repeat it","volume":"24","author":"Sarraju","year":"2025","journal-title":"Am J Prevent Cardiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/eci.70167","article-title":"Atherogenic dyslipidaemia and residual cardiovascular risk: understanding the link to heart disease","volume":"56","author":"Gir\u00f3n","year":"2026","journal-title":"Eur J Clin Invest"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.069556","article-title":"Independence of lipoprotein(a) and low-density lipoprotein cholesterol-mediated cardiovascular risk: a participant-level meta-analysis","volume":"151","author":"Bhatia","year":"2025","journal-title":"Circulation"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.073053","article-title":"Letter by Sechi et\u00a0al regarding article, independence of lipoprotein(a) and low-density lipoprotein cholesterol-medicated cardiovascular risk: a participant-level meta-analysis","volume":"152","author":"Sechi","year":"2025","journal-title":"Circulation"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arter Thromb Vasc Biol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-3-200602070-00005","article-title":"Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate","volume":"144","author":"Rahman","year":"2006","journal-title":"Ann Intern Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041365","article-title":"Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction","volume":"351","author":"Anavekar","year":"2004","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"B55","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/ehf2.13699","article-title":"Chronic kidney disease and risk of atrial fibrillation and heart failure in general-population cohorts: the BiomaCaRE project","volume":"9","author":"Rehm","year":"2022","journal-title":"ESC Heart Failure"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.14.9.1405","article-title":"Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease","volume":"14","author":"Kronenberg","year":"1994","journal-title":"Arterioscler Thromb"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(99)70147-2","article-title":"Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure","volume":"6","author":"Milionis","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.117.309920","article-title":"Lipoprotein(a) and risk of myocardial infarction and death in chronic kidney disease: findings from the CRIC study (Chronic Renal Insufficiency Cohort)","volume":"37","author":"Bajaj","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-023-01590-3","article-title":"Relationship between lipoprotein(a) levels, cardiovascular outcomes and death in patients with chronic kidney disease; a systematic review of prospective studies","volume":"36","author":"Barbagelata","year":"2023","journal-title":"J Nephrol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1016\/j.jacl.2026.06.027","article-title":"Association of lipoprotein(a) with renal disease and cardiac outcomes in chronic kidney disease: a nationwide cohort study","volume":"20","author":"Luo","year":"2026","journal-title":"J Clin Lipidol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2026.1908850","article-title":"Lipoprotein(a) and calcific aortic stenosis: from inherited risk marker to therapeutic target","volume":"13","author":"Epelde","year":"2026","journal-title":"Front Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"37524","DOI":"10.1038\/s41598-025-21517-1","article-title":"Associations between aortic valve calcification and cardiovascular events in patients with chronic kidney disease","volume":"15","author":"Hayashida","year":"2025","journal-title":"Sci Rep"},{"key":"B63","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejim.2025.03.037","article-title":"Aortic valve calcium as a novel risk marker for kidney function deterioration; the MESA study","volume":"136","author":"Abdollahi","year":"2025","journal-title":"Eur J Intern Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1159\/000553534","article-title":"Lipoprotein(a) and cardiovascular risk: emerging therapeutic perspectives with implications for chronic renal disease","volume":"16","author":"Di Lullo","year":"2026","journal-title":"Cardiorenal Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000968","article-title":"Lipoprotein(a) and CKD: insights into new therapeutic opportunities","volume":"21","author":"Byambaa","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein(a) in chronic renal disease","volume":"59","author":"Hopewell","year":"2018","journal-title":"J Lipid Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V61110","article-title":"Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis","volume":"6","author":"Kronenberg","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1993.349","article-title":"Apolipoprotein(a) phenotypes and serum lipoprotein(a) levels in maintenance hemodialysis patients with\/without diabetes","volume":"44","author":"Hirata","year":"1993","journal-title":"Kidney Int"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2010.486097","article-title":"Lipoprotein-a and carotid intima media thickness as cardiovascular risk factors in patients with chronic kidney disease","volume":"32","author":"Aggarwal","year":"2010","journal-title":"Ren Fail"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1159\/000112225","article-title":"Effects of renal replacement therapy on plasma lipoprotein(a) levels","volume":"28","author":"Rosas","year":"2007","journal-title":"Am J Nephrol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.14.9.1399","article-title":"Apolipoprotein(a) phenotype associated decrease in lipoprotein(a) plasma concentrations after renal transplantation","volume":"14","author":"Kronenberg","year":"1994","journal-title":"Arterioscler Thromb"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-9150(99)00014-3","article-title":"Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up","volume":"144","author":"Kerschdorfer","year":"1999","journal-title":"Atherosclerosis"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002131","article-title":"In vivo turnover study demonstrates dimished clearance of lipoprotein(a) in hemodialysis patients","volume":"71","author":"Frischmann","year":"2007","journal-title":"Kidney Int"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118487","article-title":"Apolipoprotein(a) kringle 4-containing fragments in human urine: relationship to plasma levels of lipoprotein(a)","volume":"97","author":"Mooser","year":"1996","journal-title":"J Clin Invest"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg181","article-title":"Relationship of non-LDL-bound apo(a), urinary apo(a) fragments and plasma Lp(a) in patients with impaired renal function","volume":"18","author":"Cauza","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-4-199308150-00002","article-title":"Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome","volume":"119","author":"Wanner","year":"1993","journal-title":"Ann Intern Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1993.357","article-title":"Lipoprotein(a) in nephrotic syndrome","volume":"44","author":"Stenvinkel","year":"1993","journal-title":"Kidney Int"},{"key":"B78","article-title":"Symptomatic antiproteinuric treatment decreases serum lipoprotein(a) concentration in patients with glomerular proteinuria","volume":"9","author":"Gansevvort","year":"1994","journal-title":"Nephrol Dial Transplant"},{"key":"B79","doi-asserted-by":"crossref","DOI":"10.1093\/clinchem\/41.6.908","article-title":"Accumulation of atherogenic remnants and lipoprotein(a) in the nephrotic syndrome: relation to remission of proteinuria","volume":"41","author":"Joven","year":"1995","journal-title":"Clin Chem"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00018.x","article-title":"Plasma alpha 2 macroglobulin is increased in nephrotic patients as a result of increased synthesis alone","volume":"54","author":"de Sain-van der Veiden","year":"1998","journal-title":"Kidney Int"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1727918","article-title":"Emerging therapies targeting lipoprotein(a): the next frontier in cardiovascular risk reduction","volume":"12","author":"Alhomoud","year":"2025","journal-title":"Front Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2004.08.001","article-title":"Omega-3 polyunsaturated fatty acids decrease plasma lipoprotein(a) levels in hypertensive subjects","volume":"23","author":"Colussi","year":"2004","journal-title":"Clin Nutr"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk: insights from the FOURIER Trial","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-025-07810-1","article-title":"Lipoprotein(a) in cardiovascular diseases and emerging therapeutic strategies","volume":"40","author":"Al-Horani","year":"2026","journal-title":"Cardiovasc Drugs Ther"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2025.06.004","article-title":"Pelacarsen: mechanism of action and Lp(a)-lowering effect","volume":"19","author":"Bhatia","year":"2025","journal-title":"J Clin Lipidol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.12.032","article-title":"Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol","volume":"79","author":"Yeang","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran \u2013 a small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial","volume":"332","author":"Nissen","year":"2024","journal-title":"JAMA"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran - a long-duration small interfering RNA targeting lipoprotein(a)","volume":"392","author":"Nissen","year":"2025","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2022.05.004","article-title":"Study design and rationale for the olpasiran trials of cardiovascular events and lipoprotein(a) reduction-DOSE finding study (OCEAN(a)-DOSE)","volume":"251","author":"O\u2019Donoghue","year":"2022","journal-title":"Am Heart J"},{"key":"B95","unstructured":"A study to investigate the effect of Lepodisiran on the reduction of major adverse cardiovascular events in adults with elevated lipoprotein(a) - ACCLAIM-Lp(a)"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.24017","article-title":"Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial","volume":"333","author":"Nicholls","year":"2025","journal-title":"JAMA"},{"key":"B97","doi-asserted-by":"publisher","first-page":"107117","DOI":"10.1016\/j.ejim.2026.107117","article-title":"Personalizing cardiovascular prevention in chronic kidney disease: an operational framework for risk-treatment mapping","author":"Zoccali","year":"","journal-title":"Eur J Intern Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11883-021-00911-w","article-title":"LDL apheresis and Lp(a) apheresis: a clinician\u2019s perspective","volume":"23","author":"Kayikcioglu","year":"2025","journal-title":"Curr Atheroscler Rep"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2006.02.030","article-title":"A systematic review of LDL apheresis in the treatment of cardiovascular disease","volume":"189","author":"Thompsen","year":"2006","journal-title":"Atherosclerosis"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/ncpcardio1456","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","author":"Jaeger","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"B101","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.jacl.2019.09.010","article-title":"Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease","volume":"13","author":"Moriarty","year":"2019","journal-title":"J Clin Lipidol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2024.04.134","article-title":"Long-term lipoprotein apheresis reduces cardiovascular events in high-risk patients with isolated lipoprotein(a) elevation","volume":"18","author":"Schumann","year":"2024","journal-title":"J Clin Lipidol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.120508","article-title":"Lipoprotein apheresis for lipoprotein(a)-associated progressive atherosclerotic cardiovascular disease: 12-years follow-up","volume":"410","author":"Klingel","year":"2025","journal-title":"Atherosclerosis"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252413597","article-title":"Reduced oxidative susceptibility of Lp(a) and LDL fractions as a pleiotropic effect of lipoprotein apheresis in patients with elevated Lp(a) and ASCVDs","volume":"25","author":"Krzesinska","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1002\/jca.70020","article-title":"Combined treatment with lipoprotein apheresis and hemodialysis in patients with severe cardiovascular disease, high lipoprotein(a) and end stage renal disease","volume":"40","author":"Roseler","year":"2025","journal-title":"J Clin Apher"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"}],"container-title":["Frontiers in Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1950030\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:50:19Z","timestamp":1791366619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1950030\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":106,"alternative-id":["10.3389\/fneph.2026.1950030"],"URL":"https:\/\/doi.org\/10.3389\/fneph.2026.1950030","relation":{},"ISSN":["2813-0626"],"issn-type":[{"value":"2813-0626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1950030"}}